At Aplagon we are developing first-in-class therapeutic treatments, APACs, to manage unmet needs in vascular medicine.

APACs target a wide range of vascular injury related blood vessel occlusions, as well as the prevention of the consequences of reperfusion ischemia. Due to the broad mode of action, APACs also have therapeutic potential in other vascular indications.